AZN - Ticker AI Digest

AstraZeneca PLC 📰 3
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (AZN) 3
AZN 06:11
AstraZeneca PLC
Fixed-duration Calquence recommended in EU for CLL
AZN 06:06
AstraZeneca PLC
Update on CAPItello-280 Phase III trial
AZN 06:01
AstraZeneca PLC
1st Quarter Results
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
AstraZeneca released its first-quarter results for 2025, reporting strong growth momentum and pipeline delivery. The companys total revenue increased by 10% to $13,588 million, driven by double-digit growth in oncology and biopharmaceuticals. Core operating profit increased by 12%, and core EPS rose by 21% to $2.49. AstraZeneca also announced five positive Phase III readouts and 13 approvals in major regions since the last earnings report. The company reiterated its full-year 2025 guidance for total revenue and core EPS growth at constant exchange rates.
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 4
AZN 06:06
AstraZeneca PLC
Imfinzi approved in EU for AEGEAN
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
AstraZenecas Imfinzi (durvalumab) has received approval from the European Commission for use in combination with chemotherapy to treat adults with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence. The approval is based on the positive results of the AEGEAN Phase III trial, which showed a 32% reduction in the risk of recurrence, progression, or death compared to neoadjuvant chemotherapy alone. Imfinzi is already approved in the US, China, and other countries for this indication, and regulatory applications are under review in Japan and other countries. Lung cancer is a leading cause of cancer-related deaths, and the AEGEAN trial demonstrated that adding Imfinzi to neoadjuvant chemotherapy improved outcomes for patients with resectable NSCLC, a population with a high unmet medical need.
AZN 06:01
AstraZeneca PLC
Enhertu approved in EU in post-ET breast cancer
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
AstraZeneca and Daiichi Sankyos Enhertu (trastuzumab deruxtecan) has received approval in the European Union for treating a specific type of metastatic breast cancer. This approval is based on the positive results from the DESTINY-Breast06 Phase III trial, which showed that Enhertu significantly improved progression-free survival compared to chemotherapy in patients with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer. The safety profile of Enhertu in this trial was consistent with previous studies. This approval expands the use of Enhertu to an earlier treatment setting and broadens the eligible patient population. Enhertu is a HER2-directed antibody-drug conjugate, jointly developed and commercialized by AstraZeneca and Daiichi Sankyo. Following this approval, AstraZeneca will make a milestone payment of $125 million to Daiichi Sankyo.
AZN 06:01
AstraZeneca PLC
Imfinzi approved in the US for bladder cancer
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
AstraZenecas Imfinzi (durvalumab) has been approved by the FDA as the first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer (MIBC). The approval was based on the NIAGARA Phase III trial, which showed a significant reduction in the risk of recurrence and death compared to neoadjuvant chemotherapy alone. The trial results demonstrated that the Imfinzi-based perioperative regimen improved event-free survival and overall survival, with an estimated 67.8% of patients being event-free at two years and 82.2% alive. Imfinzi was well tolerated, with no new safety signals observed. This approval represents a paradigm shift in the treatment of MIBC, addressing the high rates of disease recurrence and poor prognosis associated with current standard-of-care chemotherapy and surgery.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 1
AZN 06:01
AstraZeneca PLC
1st Quarter Results
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
AstraZeneca released its first-quarter results for 2025, reporting strong growth momentum and pipeline delivery. The companys total revenue increased by 10% to $13,588 million, driven by double-digit growth in oncology and biopharmaceuticals. Core operating profit increased by 12%, and core EPS rose by 21% to $2.49. AstraZeneca also announced five positive Phase III readouts and 13 approvals in major regions since the last earnings report. The company reiterated its full-year 2025 guidance for total revenue and core EPS growth at constant exchange rates.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 1
AZN 06:06
AstraZeneca PLC
Update on CAPItello-280 Phase III trial
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 10
AZN 06:11
AstraZeneca PLC
Fixed-duration Calquence recommended in EU for CLL
AZN 06:06
AstraZeneca PLC
Update on CAPItello-280 Phase III trial
AZN 06:01
AstraZeneca PLC
1st Quarter Results
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
AstraZeneca released its first-quarter results for 2025, reporting strong growth momentum and pipeline delivery. The companys total revenue increased by 10% to $13,588 million, driven by double-digit growth in oncology and biopharmaceuticals. Core operating profit increased by 12%, and core EPS rose by 21% to $2.49. AstraZeneca also announced five positive Phase III readouts and 13 approvals in major regions since the last earnings report. The company reiterated its full-year 2025 guidance for total revenue and core EPS growth at constant exchange rates.
AZN 06:01
AstraZeneca PLC
Enhertu combination improved PFS in 1L HER2+ mBC
AZN 16:31
AstraZeneca PLC
Result of AGM
AZN 06:06
AstraZeneca PLC
Imfinzi approved in EU for AEGEAN
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
AstraZenecas Imfinzi (durvalumab) has received approval from the European Commission for use in combination with chemotherapy to treat adults with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence. The approval is based on the positive results of the AEGEAN Phase III trial, which showed a 32% reduction in the risk of recurrence, progression, or death compared to neoadjuvant chemotherapy alone. Imfinzi is already approved in the US, China, and other countries for this indication, and regulatory applications are under review in Japan and other countries. Lung cancer is a leading cause of cancer-related deaths, and the AEGEAN trial demonstrated that adding Imfinzi to neoadjuvant chemotherapy improved outcomes for patients with resectable NSCLC, a population with a high unmet medical need.
AZN 06:01
AstraZeneca PLC
Enhertu approved in EU in post-ET breast cancer
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
AstraZeneca and Daiichi Sankyos Enhertu (trastuzumab deruxtecan) has received approval in the European Union for treating a specific type of metastatic breast cancer. This approval is based on the positive results from the DESTINY-Breast06 Phase III trial, which showed that Enhertu significantly improved progression-free survival compared to chemotherapy in patients with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer. The safety profile of Enhertu in this trial was consistent with previous studies. This approval expands the use of Enhertu to an earlier treatment setting and broadens the eligible patient population. Enhertu is a HER2-directed antibody-drug conjugate, jointly developed and commercialized by AstraZeneca and Daiichi Sankyo. Following this approval, AstraZeneca will make a milestone payment of $125 million to Daiichi Sankyo.
AZN 14:01
AstraZeneca PLC
Total Voting Rights
AZN 06:01
AstraZeneca PLC
Imfinzi approved in the US for bladder cancer
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
AstraZenecas Imfinzi (durvalumab) has been approved by the FDA as the first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer (MIBC). The approval was based on the NIAGARA Phase III trial, which showed a significant reduction in the risk of recurrence and death compared to neoadjuvant chemotherapy alone. The trial results demonstrated that the Imfinzi-based perioperative regimen improved event-free survival and overall survival, with an estimated 67.8% of patients being event-free at two years and 82.2% alive. Imfinzi was well tolerated, with no new safety signals observed. This approval represents a paradigm shift in the treatment of MIBC, addressing the high rates of disease recurrence and poor prognosis associated with current standard-of-care chemotherapy and surgery.

AI Crunch

Single-Ticker AI Crunch
AZN signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for AstraZeneca PLC. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full AZN AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for AZN on 2025-04-29.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
228996038656
Enterprise Value
188046885670
Public Float
99.52
Broker Target
16212.825
Shares Out
1550833276
Long Interest
100
Short Interest
-
Exchange
LSE
Currency Code
GBX
ISIN
GB0009895292
Market
LSE - MAIN MARKET
Sector
Health Care
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
2.36
Ex Divi
2026-02-19
Earnings Date
2026-02-05
Net Debt
23911000000.0
Cash
5711000000.0
EPS
4.83
Net Income
10225000000.0
Revenue
58739000000.0
Enterprise Value
188046885670
Trailing PE
30.5714
Forward PE
19.305
Price Sales TTM
3.8985
Price Book MRQ
6.2017
EV Revenue
5.722
EV EBITDA
17.2308

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
4.9735
Institutions As Of
2025-12-04
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
5
Sale Director Dealing
2
Purchase TR1
3
Sale TR1
3
Broker Coverage Rows
38
Institution Holders Tracked
1
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

3 live catalysts just hit AZN.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2025-04-29 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
3 Today
Catalyst Pulse
AstraZeneca PLC has fresh news flow feeding the chart narrative.
06:11 Today's Catalyst Fixed-duration Calquence recommended in EU for CLL 06:06 Today's Catalyst Update on CAPItello-280 Phase III trial
AI Charts Studio
AZN Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2025-04-29 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast 36.77%
RSI Gauge
Price Change
AI Forecast